The economic burden of Type 2 Diabetes by social determinants of health: A systematic review Authors: Dulce E. Alarcón-Yaquetto, Robert Stewart, Khalida Ismail, James Shearer, Pasyodun Koralage Buddhika Mahesh, Pasyodun Koralage Buddhika Mahesh, Pasyodun Koralage Buddhika Mahesh Published: 2026 ABSTRACT BackgroundThe unequal distribution of resources in society generates social gradients that translate into health inequalities and differential use of health care resources and their costs. Non-medical factors such as employment, income, ethnicity and education impact the prevalence and treatment outcomes of patients with type 2 diabetes mellitus (T2DM); however, there is a scarcity of articles assessing the relationship between health inequalities and the economic costs of treatment. Therefore, we conducted a systematic review of published studies examining the cost differences of treating T2DM across social determinants of health (SDH).MethodsWe systematically searched MEDLINE, Embase, PsycINFO, EconLit, and NHS EED for original peer-reviewed articles that provided cost differences of treating T2DM by SDH: education, income, employment, residency and ethnicity. We grouped the studies by each SDH and calculated the percentage differences where possible between the lowest and highest ends of the gradient (education, income and employment). Residency was categorised as rural vs. urban and ethnicity as white or general population vs other ethnic minorities.ResultsWe included 19 articles retrieved internationally from varying healthcare systems. Results were contextualised given the healthcare financing model. In countries with high out-of-pocket expenses, Black and Hispanic ethnic backgrounds and rural residence were associated with lower direct health care and costs likely to be determined by ability to pay rather than clinical need. Indirect costs such as lost productivity due to absenteeism were also lower in unemployed, and lower income groups.ConclusionsThere are evident health disparities in the direct and indirect economic consequences of T2DM. The effect of decreased healthcare use and costs on treatment outcomes needs to be further explored to inform policies to ensure healthcare delivery is based on clinical need rather than socio-economic factors. Introduction Inequality describes the uneven distribution of material resources or opportunities within society. Social variables such as gender, ethnicity, education, and income, among others, shape these opportunities and create a gradient of inequality [1,2]. The impact of inequality on health has been widely documented [3] and there is consensus that social, non-medical factors can determine health outcomes, thus referred to as social determinants of health (SDH) [4]. Chronic diseases —where lifestyle plays a strong role in aetiology and recovery— are greatly affected by SDH [5]. Unhealthy lifestyles are often grouped into clusters associated with social structures and living conditions that restrict the availability and accessibility of healthy choices. These social structures are generally marked by differences in gender, ethnicity, income, and social position [6]. There is ample evidence on the impact of SDH on type 2 diabetes (T2DM) prevalence and complications. For example, a systematic review showed that economic inequalities affect the number of complications in people with T2DM [7], and glycaemic control was also found to be affected by SDH in varying degrees [8], while an interaction between socioeconomic deprivation and genetic predisposition might explain the increased prevalence of the condition in people from South Asian and African backgrounds [9]. Therefore, addressing inequalities is emphasised as means to reduce T2DM incidence and improve health outcomes of people with T2DM [10]. T2DM was selected as the focus of this review because it is among the most prevalent chronic conditions globally and one of the most strongly socially patterned, with its aetiology, management, and complications associated to modifiable lifestyle factors that are themselves shaped by SDH [5,6]. T2DM management is largely ambulatory, requiring sustained engagement with primary care, medication adherence, dietary change, and self-monitoring, which makes it sensitive to the access and resource barriers that vary across the social gradient. T2DM is a significant driver of healthcare expense around the world. Direct costs which encompass the expenses associated with the diagnosis, treatment, and management of the condition are projected to cost 1.51 trillion dollars worldwide by 2030. Indirect costs such as productivity losses due to absenteeism or premature death will reach 0.73 trillion dollars globally according to the same estimation [11]. In addition, intangible costs —those related to the burden of living with T2DM— have also been estimated although less frequently as they are much harder to assess. For instance, one study estimated these at $497 (2019 USD) per person per year in a developing country [12]. SDH also determine health service use, although the direction is not universal and is often country specific. For example, in the UK, a steep gradient in inpatient hospital admissions associated with neighbourhood deprivation has been reported. The costs were estimated at £4.8 billion a year which were partially offset by the lower life expectancy of the most deprived groups [13]. While in Sweden, even after adjusting for age and sex, the highest income groups had increased per capita health expenditures [14]. However, in general, the costs of T2DM according to SDH have not been thoroughly assessed. Given that T2DM imposes a significant financial impact on healthcare systems and this is potentially greatly affected by SDH, this review aimed to analyse published evidence on the economic burden of health disparities as defined by SDH in the treatment of people with T2DM. While the impact of SDH on T2DM prevalence, complications, and glycaemic control has been systematically reviewed, the economic costs of T2DM according to SDH have not been synthesised. To the best of our knowledge, this is the first systematic review to synthesise the economic costs of T2DM by SDH. Beyond documenting these costs, this review identifies that the direction of cost inequality is moderated by healthcare system structure, generating a conceptual framework that may have broader applicability to chronic disease cost research. Methods Search strategy The protocol of the review was registered on PROSPERO (code CRD42023444818) and is available at https://osf.io/w9nku/files/n9j34. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines [15]. The Medical subject headings (MeSH) terms used included: type 2 diabetes, non-insulin dependent diabetes, social determinants of health, health inequalities, healthcare disparities, socioeconomic factors, cost of illness, healthcare costs and hospital costs. The complete search strategy and PRISMA checklist are presented in supplementary file 1 and 2 respectively. Study selection and data extraction We included observational studies (cross-sectional, cohort, and case-control designs) reporting costs of type 2 diabetes mellitus in relation to social determinants of health. Interventional studies, including randomised controlled trials, cost-effectiveness analyses, simulation studies, and economic modelling studies, were excluded. No restrictions were applied based on country or language. All searches were limited to human studies. We also excluded book chapters, communications, editorials, and conference abstracts. The search took place on 2nd of June 2023. An update was performed the 5th of October 2025. The following databases were searched: MEDLINE, Embase, PsycINFO, EconLit, and NHSeed. Extracted data included country, design, sample size, economic approach, and perspective as well as SDH assessed and cost components. Data was extracted by DEAY from tables, text, or graphs from the original articles. We also evaluated the type of healthcare system in which each study was conducted to contextualise and discuss the results more effectively.Extracted data was compiled in a Microsoft Excel spreadsheet and managed with Mendeley v1.19.8. Titles and abstracts were reviewed by two researchers (DEAY and JS). When there were divergences, the full text was retrieved. If there was hesitation about the inclusion of a study, the reviewers discussed until a consensus was reached. The outcome of interest were direct, indirect or intangible costs of T2DM by social determinants of health (SDH). As per their definition, SDH are shaped by political, social and economic forces and are heavily influenced by the distribution of resources. Although the gradient and nature of SDH vary across countries, negative determinants tend to cluster in poorer countries, leading to greater inequities in SDH and, consequently, to health inequalities [16]. For this reason, in the present study, our primary outcome is SDH, used as a proxy for inequality. All included studies reported costs associated with at least one SDH. Residency, education, employment, income, and ethnicity were included as SDH. Gender was excluded as most studies on healthcare costs tend to focus on biological sex rather than gender, which refers to socially constructed norms shaping lifestyles and behaviours. Biological sex, while associated with differences in T2DM prevalence and onset of complications through the protective effect of estrogen [17,18],. is a biomedical rather than social determinant and falls outside the SDH framework. Gender norms may influence cost-relevant behaviours such as health-seeking and treatment adherence. In keeping with the definition of SDH, which refers specifically to non-medical factors, we chose not to include biological sex in our analysis. Data synthesis To allow a better comparison of cost differences, we calculated the percentage difference in each of the studies and grouped the results by SDH. We present these results as comparisons between the lowest and highest categories of each social determinant and by type of costs (direct, indirect, intangible). We took this approach as the operationalisation of each SDH varied by study. For education and income, percentage differences were calculated between the ones at the lowest education/income category vs those at the highest. For employment, we provide percentage differences between unemployed vs employed. For residence, we compared rural vs urban. For ethnicity and/or race, terms used interchangeably across included studies, we compared ethnic or racial minority groups against white populations or the general population, as defined by each study. The conflation of race and ethnicity across studies represents a source of heterogeneity, as racial categories (i.e., Black, White) reflect socially constructed classifications based on perceived physical characteristics, while ethnic categories reflect shared cultural or ancestral identity [19,20]. Where studies explicitly used racial rather than ethnic categories, we retained the original authors’ terminology. Percentage differences represent the relative difference in costs for the disadvantaged group compared with the reference group. For example, a reported percentage difference for lower versus higher educational attainment indicates how much higher or lower the costs were for less educated individuals relative to those with the highest level of education. Percentage differences have limitations as a comparative metric when SDH categories are defined inconsistently across studies. For example, ‘low income’ may refer to the bottom quartile in one study and below a specified amount in another, meaning that percentage differences reflect within-study gradients rather than directly comparable cross-study magnitudes. Therefore, these figures should be taken with caution and as indicative of the direction and approximate scale of cost inequalities within each SDH category rather than comparable estimates. Some studies did not provide a statistical analysis of their results, or only provide crude or adjusted p-values. We provide both values when available and report if adjusted or crude p-values were not given. In text, any non-significant result means the p value was above 0.05. The results are presented graphically. Due to the high heterogeneity of the retrieved studies, a meta-analysis was not feasible. Quality assessment The quality was assessed using Larg and Moss tool for cost-of-illness studies [21] which analyses three main domains: analytical framework, methodology and data, and analysis and reporting. Each with subdomains that allow a comprehensive appraisal of the study such as the perspective, epidemiological approach, and the methodology used to quantify the costs. Each item was rated as low risk of bias, high risk of bias, unclear or no information. Quality appraisal was conducted by one reviewer (DEA-Y). Where uncertainty arose regarding the classification of individual items, assessments were discussed with a second reviewer (JS) to reach consensus. The results are presented graphically using robvis package [22] in RStudio. Results Included studies The initial search yielded 5819 unique studies of which 5488 were excluded as they were deemed irrelevant to the research question, 331 studies underwent full review and 22 were selected for analysis. An updated search conducted in October 2025 identified an additional 642 records. Of these, 21 studies were assessed at the full-text stage; however, none met the inclusion criteria, and no additional studies were included in the final analysis. The complete study selection process is illustrated in Fig 1. PRISMA flowchart. The median sample size was 10575 (range: 1021−32,846). Most studies had a cross-sectional design (68%), and publications dates ranged from 2000 to 2021. Table 1 presents further characteristics of the studies analysed. 10.1371/journal.pone.0354198.t001Table 1Characteristics of the selected studies.ArticleCountryDesignSample sizeData sourceApproachPerspectiveCountry’s healthcare modelReference Afroz 2019 BangladeshCross-sectional1253Hospital records and questionnairesPrevalencePatientsOut-of-pocket[23] Le 2013 ChinaCross-sectional9396Community health interview and surveyPrevalenceSocietalOut-of-pocket[24] Lee 2006 USACross-sectional1021SurveyNRNRMixed[25] Li 2015 USAProspective11927Survey, medical records and administrative dataNRHCMixed[26] Daniel 2021 IndiaProspective300Medical bills, records and questionnairesNRNROut-of-pocket[27] Dawson 2021 USACross-sectional17820243SurveyNRNRMixed[28] Endarti 2020 IndonesiaCross-sectional131QuestionnairesPrevalencePatientsMixed[29] Guo 2021 ChinaPopulation based survey17708SurveyNRSocietalOut-of-pocket[30] Hazel Fernández 2015 USARetrospective333576Medical claimsNRNRMixed[31] Hu 2015 USALongitudinal32846SurveyNRNRMixed[32] Jacobs 2000 CanadaCross-sectional894420Healthcare records and registriesNRNRNational Health Insurance[33] Jing 2019 ChinaCross-sectional1948QuestionnaireNRNROut-of-pocket[34] Kim 2011 KoreaCross-sectional2752Hospital electronic databases and questionnairesNRNRNational Health Insurance[35] Konig 2021 GermanyCross-sectional325SurveyNRSocietalInsurance based[36] Kumar 2008 IndiaCross sectional1153SurveyNRNROut-of-pocket[37] Khowaja 2007 PakistanCross-sectional353QuestionnairePrevalenceSocietalOut-of-pocket[38] Simmons 2019 USACross-sectional17702SurveyNRNRMixed[39] Sun 2018 ChinaCross-sectional661QuestionnaireNRSocietalOut-of-pocket[40] Williams 2020 USALongitudinal11755SurveyNRNRMixed[41]NR: Not reported, NA: Not applicable. Characteristics of the selected studies. NR: Not reported, NA: Not applicable. Twelve studies evaluated only direct costs [25,26,28,30–35,37,39,41], while seven evaluated both [23,24,27,29,36,38,40]. One study from the latter group also evaluated intangible costs [24]. Some studies further classified direct costs as medical and non-medical costs. The former refers to all medical procedures and physician fees associated with medical treatment while the non-medical category includes cost of transportation, accommodation and meals while traveling to the healthcare centre. Table 2 provides detailed information of what costs and components were analysed in each study and the cost allocation method used. 10.1371/journal.pone.0354198.t002Table 2Types of costs, components and costing methods used in included studies.ArticleType of direct costsCost allocation direct costsType of indirect costCost allocation indirect costsIntangiblesCounterfactualSDH analysed Afroz 2019 Direct medical (hospitalisation, outpatient visits, medicine, laboratory tests, glucose monitoring, laboratory tests and consumables)Direct non-medical (transportation and meals to hospital)Bottom-up (micro-costing)Patients and carers’ productivityHuman capital approachNANoneResidence, Education, Employment, Income Le 2013 Direct medical (hospitalisation, outpatient visits, and medication)Direct non-medical costs (transportation for the patient and carers to and from healthcare providers, accommodation, and costs of hiring nurses or other care providers)NRProductivity loss due to premature mortality and productivity loss related morbidityHuman capital approachContingence valuation willingness to pay approach on losses due to physical and psychological complicationsNoneEducation Lee 2006 Direct medical (ambulatory care visits and prescription drug fills). Disaggregated in payments by insurance and OOPNRNANANANone. Comparisons made between T2DM patients by ethnicityEthnicity Li 2015 Direct medical (inpatient, outpatient, emergency, pharmacy, radiology and laboratory tests)NRNANANoneNoneEthnicity, Education, Income Daniel 2021 Direct medical (hospital services, physician services, laboratory tests, daily management, medicines, consultations, hospitalisations)NRLoss of productivity due to sickness. Monthly income loss of patient and carer. Transportation and other ancillary costs were considered indirect costs.Daily wages multiplied by number of absent daysNone. T2DM patients grouped between rural vs urbanResidence Dawson 2021 Direct medical (office-based medical provider expenditure, outpatient, inpatients, emergency, prescriptions, dental expenditure, home health care expenditure) whether OOP or paid by insurance providerNRNANANANoneEthnicity Endarti 2020 Direct medical costs (administration, healthcare professionals, laboratory test cost, drug and medical item costs).Direct non-medical (meal and transportation of patients and caregivers)NRProductivity loss of patients and caregiversHuman capital approachNANoneEmployment, Income Guo 2021 Direct medical costs (medications and tests, outpatients, inpatients visits, and self-health care).Direct nonmedical costs (transportation, visits by relatives and/or friends during inpatient and outpatient periods, accommodations, and food)NRNANANANone. Population was divided in patients with diagnosed T2DM and those with undiagnosed T2DM. Costs extracted refer to diagnosed T2DMResidence, Education, Employment, Income Hazel Fernández 2015 Direct medical costs (all-cause medical and pharmacy claims, irrespective of diagnosis or therapeutic class for the respective medications, outpatient and inpatient hospitalisation use, emergency)NRNANANANone. Comparisons made between T2DM patients by ethnicityEthnicity Hu 2015 Direct medical costs (medical care, hospital use, physician office visits, and prescription drug use) whether OOP or paid by insurance providerNRNANANAYes. Non-diabetes groupEducation, Employment, Income, Ethnicity Jacobs 2000 Direct medical costs (physician fees, personal care home days, hospitalisation, outpatient dialysis)NRNANANAYes. Population was grouped in First Nation and General Population. Each group was subdivided in those with or without T2DMEthnicity Jing 2019 Direct medical costs (outpatient, inpatient, physical examinations)NRNANANANoneResidence Kim 2011 Direct medical costs (diagnosis, outpatients, hospitalisation, pharmacological therapy and cost of complementary alternative medicine)NRNANANANone. T2DM population was grouped between CAM users vs non users. Cost provided in the analysis belong to non-users.Education, Income, Konig 2021 Direct (outpatient, inpatient, rehabilitation and medication)Bottom-upSick leave and early retirementHuman capital approachNAYes. Patients with T2DM and non-T2DMEducation, Kumar 2008 Direct medical (consultations, medicines, tests, monitoring)NRNANANANoEducation, Employment, Income, Khowaja 2007 Direct medical (consultations, investigations, medicine)Direct non-medical (travel and food)Top downLoss productivity because of disability and premature death and loss of time (travelling, waiting, getting healthcare) of patients and carersHuman capital approachNANoEducation, Income Simmons 2019 Direct medical OOP (medical provider, non-physician services, inpatients, emergency, dental care, medications)NRNANANAT2DM sample divided by ethnicity. No counterfactual.Ethnicity Sun 2018 Direct medical (outpatient, inpatient, drugs, medical equipment)Direct non-medical (transportation, accommodation, costs providing nutritional food according to special needs of T2DM patients)NRProductivity loss of patients and carersLost earnings due to lost workdaysT2DM population divided by Hui and HanEthnicity Williams 2020 Direct medical (healthcare, hospital and emergency visits, pharmacy and home-health care)NRNANANAT2DM only women patients were divided by ethnicityEthnicityOOP: Out-of-pocket, T2DM: Type 2 diabetes mellitus, CAM: complementary alternative medicine, NA: Not applicable, NR: Not reported. Types of costs, components and costing methods used in included studies. OOP: Out-of-pocket, T2DM: Type 2 diabetes mellitus, CAM: complementary alternative medicine, NA: Not applicable, NR: Not reported. Healthcare models Seven studies were set in the US, which has a mixed healthcare model with low level of government intervention [42]. In 2020, 9% of the US population were not covered by any health insurance. Private health insurance coverage was more prevalent than public coverage at 67% and 35%, respectively [43]. In 2022, 11% of US health care expenditures were paid out of patients’ pockets directly or through deductibles [44]. Four studies were set in China, where the healthcare system has undergone major reforms in recent years aiming for universal coverage and decreasing catastrophic OOP expenditure [45]. Now, citizens are enrolled either in the employee basic medical insurance programme or the non-working residents’ scheme which also serves rural populations [46]. However, in 2016, 29% of Chinese residents still incurred healthcare OOP expenses [45]. Countries in South Asia (Bangladesh, India, Pakistan) were also represented in the selected studies. These are examples of countries where the patient is the main bearer of costs. In Bangladesh, 64% of overall healthcare expenditure is OOP [47], 63% in India [48] and 88% in the private sector in Pakistan [49]. In Indonesia, where one study was conducted, the healthcare systems is fragmented. Until 2014, Indonesia had employment-based insurance schemes, public assistance services for the uninsured, and a private sector, until a reform scheme came into place that sought to unify multiple fragmented programmes, it now covers 83% of their population [50]. Canada and South Korea, with one study each, have a National Health Insurance model where the providers are private, and the funds are public [51,52]. The coverage of basic medical and hospital costs is complete and in Canada, without direct charges at the point of delivery. In Korea, patients pay 30% of outpatient medical and prescriptions costs [53]. Finally, Germany (one study) has an insurance system financed by employers and employees through payroll deduction. Insurance plans do not make profit and include all citizens [54]. It is possible to opt out of the insurance scheme in certain cases, such as being a high-earner [55]. Primary outcomes Findings were conflicting for education, income, and employment, while residence, and ethnicity showed clearer and more sustained trends across studies. Residence. Residence status was ascertained by urban or rural settings in 4 studies, all set in the Asian continent [23,27,30,34]. All four studies reported that the direct cost of treating T2DM in rural settings was lower than the treatment of urban patients. Two studies also reported decreased indirect costs [23,27]. The differences ranged from 18% [34] to 71% [27] (Fig 2A). Out-of-pocket (OOP) expenditure was reported in three studies as part of direct medical costs [24,27,30,34]. Guo reported OOP being higher in rural areas [30], Daniel reported higher catastrophic OOP costs in urban areas [27] and Jing reported no difference in OOP costs but the proportion of the OOP relative to their total income was higher for rural patients [34]. Percentage difference according to (A) Residence status, (B) Education, (C) Employment and (D) Income. Education. Data regarding education was mixed. Nine studies provided costs by this SDH. Five provided only direct costs, and four provided both. Additionally, one study from the latter group also provided intangible costs [24]. Regarding direct costs, three studies reported that people with lower educational attainment had higher costs than their higher educated counterparts [24,26,35]. Only crude p values were reported. On the other hand, five studies reported decreased direct costs in people with lower educational level [23,30,32,37,38]. Some studies reported significant differences even after adjusting by other social variables and comorbidities [30,32,37] and pharmacological adherence [37] (Fig 2B). Intangible costs, defined as the willingness to pay to avoid the physical and psychological strain of T2DM, were 41% lower for less educated people [24] (Table 3, Fig 2B). Four studies reported that lower education was associated with decreased indirect costs, mainly assessed by the loss of productivity of the patient and their carers due to the disease [23,24,36,38]. Three reported significant differences in crude models while one reported 35% less indirect costs but does not provide statistical testing. 10.1371/journal.pone.0354198.t003Table 3Summary of percentage cost differences in the treatment of type 2 diabetes by social determinant of health, grouped by region and healthcare model.SDHRegionHealthcare modelStudySDH operationalisationCost type% differenceDirection Residence AsiaOOPDaniel 2021Rural vs UrbanDirect64.23% *, nr↓ Rural Residence AsiaOOPAfroz 2019Rural vs UrbanDirect61.36% *, nr↓ Rural Residence AsiaMixed/OOPJing 2019Rural vs UrbanDirect18.95% nr Residence AsiaMixed/OOPGuo 2021Rural vs UrbanDirect50.52% *, *↓ Rural Residence AsiaOOPDaniel 2021Rural vs UrbanIndirect70.95% *, nr↓ Rural Residence AsiaOOPAfroz 2019Rural vs UrbanIndirect33.72% *, nr↓ Rural Residence AsiaMixed/OOPGuo 2021Rural vs UrbanIndirect26% *, ns↓ Rural Education USAMixedLi 2015Less than high school vs completed collegeDirect21.95% *, nr↑ Less than high school Education USAMixedHu 2015No degree vs above BachelorDirect8.35% ns, *↓ No degree Education AsiaOOPAfroz 2019Illiterate vs TertiaryDirect21.61% *, nr↓ Illiterate Education AsiaMixed/OOPLe 2013Illiterate vs higher than middle schoolDirect10.52% *, nr↑ Illiterate Education AsiaMixed/OOPKumar 2008Illiterate vs PostgraduateDirect51.26% nr,*↓ Illiterate Education AsiaMixed/OOPKhowaja 2007Illiterate vs Higher than secondaryDirect74.46% *, nr↓ Illiterate Education AsiaMixed/OOPGuo 2021Primary vs high schoolDirect38.28% ns,*↓ Illiterate Education AsiaOOPAfroz 2019Illiterate vs TertiaryIndirect41.05% *, nr↓Illiterate Education AsiaMixed/OOPLe 2013Illiterate vs higher than middle schoolIndirect40.12% *, nr↓ Illiterate Education AsiaMixed/OOPKhowaja 2007Illiterate vs Higher than secondaryIndirect81.56% *, nr↓ Illiterate Education AsiaMixed/OOPGuo 2021Primary vs high schoolIndirect38.88% *, ns↓ Illiterate Education AsiaMixed/OOPLe 2013Illiterate vs higher than middle schoolIntangible57.25% *, nr↓ Illiterate Education AsiaNational Health InsuranceKim 2011Less than high school vs More than High SchoolDirect27.8% *, nr↑Less than High School Education EuropeInsurance basedKonig 2021Low vs HighDirect2.14% nr Education EuropeInsurance basedKonig 2021Low vs HighIndirect34.88% nr Employment AsiaMixed/OOPKumar 2008Unemployed vs EmployedDirect20.58% *, ns↑ Unemployed Employment AsiaMixed/OOPGuo 2021Unemployed vs EmployedDirect3.95% *, ns↑ Unemployed Employment AsiaMixedEndarti 2020Unemployed vs EmployedDirect336% *, nr↑ Unemployed Employment AsiaOOPAfroz 2019Unemployed vs EmployedDirect4.78% *, nr↑ Unemployed Employment USAMixedHu 2015Unemployed vs EmployedDirect91.62% *,*↑ Unemployed Employment AsiaMixedEndarti 2020Unemployed vs EmployedIndirect94.17% *, nr↓ Unemployed Employment AsiaOOPAfroz 2019Unemployed vs EmployedIndirect58.62% *, nr↓ Unemployed Employment AsiaMixed/OOPGuo 2021Unemployed vs EmployedIndirect17.6% *, ns↑ Unemployed Income AsiaOOPAfroz 2019MHI < US$250 vs US$751+Direct25.05% *, nr↓ MHI < US$250 Income AsiaMixedEndarti 2020<3,000,000 vs ≥ 3,000,000Direct161.43% ns, nr↓ < 3,000,000 Income AsiaMixed/OOPGuo 2021Lowest 20% vs Highest 20%Direct71.86% ns, *↓ Lowest 20% Income AsiaMixed/OOPKumar 2008YI < 0.36 million INR vs > 1.2 millionDirect43.5% nr,*↓ YI < 0.36 million INR Income AsiaMixed/OOPKhowaja 2007MHI < 5000 PKR vs > 20000 PKRDirect76.29% *, ns↓ MHI < 5000 PKR Income AsiaNational Health InsuranceKim 2011MHI US$ < 2000 vs > 40000Direct9.98% *, nr↑ MHI US$ < 2000 Income USAMixedLi 2015YI < $15000 vs > 74999Direct59.24% ns, nr Income USAMixedHu 2015$40000Direct10.77% *,ns↑ < US$20000 Income AsiaMixed/OOPKhowaja 2007MHI < 5000 PKR vs > 20000 PKRIndirect84.48% *, ns↓ MHI < 5000 PKR Income AsiaMixedEndarti 2020<3,000,000 vs ≥ 3,000,000Indirect65.08% *, nr↑ < 3,000,000 Income AsiaMixed/OOPGuo 2021Lowest 20% vs Highest 20%Indirect48.68% ns, ns Income AsiaOOPAfroz 2019MHI < US$250 vs US$751+Indirect52.75% *, nr↓ MHI < US$250 Ethnicity CanadaNational Health InsuranceJacobs 20001st nation vs generalDirect68.56% (nr) Ethnicity AsiaMixed/OOPSun 2018Hui vs HanDirect26.65% (*, *)↓ Hui Ethnicity AsiaMixed/OOPSun 2018Hui vs HanIndirect74.92% (*, *)↓ Hui Ethnicity USAMixedDawson 2021Hispanic vs Non Hispanic WhiteDirect32.54% (nr, *)↓ Hispanic Ethnicity USAMixedHazel-Fernandez 2015Hispanic vs Non Hispanic WhiteDirect10.66% (*, nr)↓ Hispanic Ethnicity USAMixedHu 2015Hispanic vs Non Hispanic WhiteDirect34.21% (*, *)↓ Hispanic Ethnicity USAMixedLee 2006Hispanic vs Non Hispanic WhiteDirect18% (ns, *)↓ Hispanic Ethnicity USAMixedLi 2015Hispanic vs Non Hispanic WhiteDirect26.21% (ns,*)↓ Hispanic Ethnicity USAMixedSimmons 2019Hispanic vs Non Hispanic WhiteDirect38.38% (ns,*)↓ Hispanic Ethnicity USAMixedWilliams 2020Hispanic vs Non Hispanic WhiteDirect41.66% (*, *)↓ Hispanic Ethnicity USAMixedDawson 2021Non Hispanic Black vs Non Hispanic WhiteDirect4.42% (nr, ns) Ethnicity USAMixedHazel-Fernandez 2015Non Hispanic Black vs Non Hispanic WhiteDirect3.02% (*, nr)↓ NHB Ethnicity USAMixedHu 2015Non Hispanic Black vs Non Hispanic WhiteDirect0.69% (*,ns) Ethnicity USAMixedLee 2006Non Hispanic Black vs Non Hispanic WhiteDirect10.52% (ns, *)↓ NHB Ethnicity USAMixedLi 2015Non Hispanic Black vs Non Hispanic WhiteDirect15.59% (ns, *)↓ NHB Ethnicity USAMixedSimmons 2019Non Hispanic Black vs Non Hispanic WhiteDirect26.62% (ns, *)↓ NHB Ethnicity USAMixedWilliams 2020Non Hispanic Black vs Non Hispanic WhiteDirect11.75% (ns,*)↓ NHB Ethnicity USAMixedDawson 2021Other vs Non Hispanic WhiteDirect33.61% (nr, *)↓ Other Ethnicity USAMixedHazel-Fernandez 2015Other vs Non Hispanic WhiteDirect21.86% (*, nr)↓ Other Ethnicity USAMixedHu 2015Other vs Non Hispanic WhiteDirect18.65% (*,ns)↓ Other Ethnicity USAMixedLi 2015Other vs Non Hispanic WhiteDirect14.67% (ns, *)↓ Other Ethnicity USAMixedSimmons 2019Other vs Non Hispanic WhiteDirect21.37% (ns, *)↓ OtherMHI: Monthly household income, YI: Yearly income. *p < 0.05 When two values are given the 1st, one represents crude p value and the 2nd the adjusted. ns: not significant, nr: not reported. Summary of percentage cost differences in the treatment of type 2 diabetes by social determinant of health, grouped by region and healthcare model. MHI: Monthly household income, YI: Yearly income. *p < 0.05 When two values are given the 1st, one represents crude p value and the 2nd the adjusted. ns: not significant, nr: not reported. Employment. Among the studies that reported inequality based on employment status, two found no significant difference in direct costs [30,37]. Direct costs in Bangladeshi patients with T2DM were found to be 5% higher in unemployed patients compared to employed ones (Fig 2C, p < 0.05 in crude analysis) [23]. Interestingly, this study found that housewives and retired patients were those with the highest cost: respectively 21% and 39% higher compared to unemployed patients [23] (p < 0.05 crude between-group comparison). In the US, Hu found significant increased direct costs for the unemployed in a representative sample of adult US patients in both crude and adjusted models [32]. Guo found that retired and self-employed patients had highest direct costs; however, when adjusting the model by other sociodemographic variables, employment was not associated with increased costs [30]. Regarding indirect costs, Endarti et.al. and Afroz et.al. found that unemployed people had significantly lower indirect costs than employed people [23,29] (Fig 2C). Income. Eight studies presented cost of T2DM by income (Fig 2D). Four out of the seven studies that reported direct costs found that people with less income incurred lower direct costs [23,30,37,38]. Kim, however, reported that those with less income were associated with significantly higher costs to the universal national health insurance system in Korea [35]. The remaining studies found no significant difference. Regarding indirect costs, there was consistency in reporting lower income associated with significant decreased indirect costs in Bangladesh, Pakistan, and the USA (Fig 2D). Ethnicity. Seven studies set in the US analysed the costs of treating T2DM by ethnicity. The median (p25-p75) sample size of the studies was 16,065 (11,841−183,211). White individuals incurred highest direct healthcare expense compared to Black [25,26,28,31,39,41], Hispanic [25,26,28,31,32,39,41] and other ethnicities [26,28,31,39] (Fig 3A). Percentage difference according to ethnicities (A) White, Hispanic and Black ethnicities, (B) Other ethnicities. NHB: Non-Hispanic Black, H: Hispanic, NHW: Non-Hispanic White. *p < 0.05 When two values are given the 1st, one represents crude p value and the 2nd the adjusted. ns: not significant, nr: not reported. Finally, two studies reported costs by ethnic minorities in Canada and in China (Fig 3B). The Canadian study reported that aboriginal First Nation people with T2DM had increased direct healthcare costs compared to non-aboriginal patients [33], with the higher costs driven by 2.74 higher hospital admission rates. On the other hand, Sun et.al. reported that the Hui ethnic minority in China had significantly lower direct and indirect costs than Han Chinese patients [40]. The indirect costs were explained by the high rates of unemployment and lower income in the Hui while the medical expenditures showed an interesting trend: the authors used quantile regression analysis and found that in the lower quantiles of expense, i.e., healthcare components with lower costs, Hui expenses were significantly lower in crude models but adjusted by education, income and comorbidities, the association was lost. However, in the highest quantile the trend was reversed, and the Hui incurred significantly higher cost than the Han even after adjusting for other variables. Table 3 summarizes these findings and are grouped by region and healthcare model. Quality of the studies The quality of the studies plot based is presented in Fig 4. Traffic light plot showing the risk of bias in each domain analysed according to the Larg and Moss appraisal checklist for cost-of-illness studies. Most of the studies were of high quality, with low risk of bias in domains such as the data for cost allocation or the assumptions made for the quantification of resources. The major concerns arose from a lack of detail on the perspective of the study, with only 8 studies reporting this explicitly. Knowing which perspective is taken is essential to ascertain potential biases that might be triggered if the perspective is only that of the cost-bearer. Furthermore, most studies did not state the epidemiological approach, or perform a sensitivity analysis although this might be due to a lack of standardised guidelines for the reporting of cost studies. Counterfactuals were missing from 77% of studies, mainly because the purpose of the studies were not to assess the cost attributed to T2DM, but the effect of SDH on costs, whether direct or indirect. A counterfactual is a hypothetical scenario where the study population does not have T2DM but is otherwise identical in all other respects [21]. Instead of analysing a counterfactual (non-T2DM scenario), most studies divided their population based on SDH characteristics. This information is collated in Table 2. We did not subtract quality points if a counterfactual was missing. Discussion The objective of this review was to assess the cost of inequality in the treatment of T2DM. To achieve this, it is essential to discuss the results in the appropriate context. We note that even though we discuss some results considering the healthcare model of the country in which each study was set, it is not the purpose of this article to discuss healthcare financing as a driver of inequalities. To interpret the findings of this review, we propose a conceptual framework (Fig 5) comprising two hypotheses that explain how inequalities impact T2DM treatment costs, moderated by each country’s healthcare system structure. These hypotheses are not mutually exclusive and may represent different stages of healthcare engagement among people experiencing inequality. Conceptual framework illustrating how social determinants of health (SDH) influence the economic costs of treating type 2 diabetes mellitus, moderated by healthcare system type. The first hypothesis: Foregone care: people experiencing inequalities incur lower direct medical costs due to their limited ability to afford the time and resources needed for regular medical visits and treatments. This is supported by articles reporting lower direct costs in rural areas in China, India and Bangladesh where costs are usually paid by the patient. Inequality due to rural residence is linked to lower incomes [56] which in turn only permit uptake of lower-cost treatment options [57]. However, the inequality suffered by rural populations is also experienced in healthcare services and infrastructure which might account for the lower direct costs. Specifically, high-complexity hospitals are not available in Chinese rural areas [58], personnel only work during the daytime in Indian rural healthcare centres [27] and, in Bangladesh and India, healthcare infrastructures and workforce have less provision in rural zones [59–61]. Associations with lower income also support this first hypothesis. In particular, countries where costs were found to be lower in the less well-off have mixed models of healthcare with high OOP. Therefore, the lower cost found is most likely to be associated with poor capacity and/or willingness to pay. Health-care utilization depends on the need for care, awareness of the need, willingness, and accessibility of care [62]. Where patients must bear the cost of a disease, the usage of services might be more associated with capacity and willingness to pay than to clinical needs. Second hypothesis: Accumulated burden. Inequality leads patients to experience higher direct medical costs in the long run, as inadequate prevention and low access to primary care could lead to the earlier onset of severe complications. While overall results were conflicting, less educated patients tended to have higher direct medical costs: 1) in South Korea, a nation with universal healthcare insurance; 2) in the Chinese rural province of Yunnan, one of the poorest areas of Southwest China with 70% of its population working as farmers, where new rural insurance schemes decrease the odds of patients not seeking healthcare due to capacity to pay; 3) in a US study that analysed patients from a managed care organisation. In the last of these, the sample included patients from 8 different healthcare plans but uninsured patients or those who pay out of pocket were not represented [26]. The increased cost observed in illiterate or less educated patients might reflect lower health literacy, as there is evidence of an association between these factors [63]. Higher health literacy is associated with better health outcomes and a differentiated use of health services. Health literate patients use primary care services more [63] whereas less health literate patients use more emergency services [64] which tend to be costlier. The Chinese and US studies found increased costs but did not provide cost component differentiation. This mediation needs to be thoroughly explored in T2DM for a better understanding of the drivers of allocation of resources. There were, however, other conflicting results. Less educated patients tended to have lower direct medical costs in countries that do not provide universal healthcare access such as India. Higher educated patients might access more and costlier treatment options than those less educated as they are likely to be in higher paying jobs and have easier access to treatments. In South Korea, the cost of the less deprived were also found to be higher. This might reflect genuine clinical need, increased survival, increased severity of the condition or more complications as the lack of access barrier is gone. In countries with a similar healthcare system to the South Korean model, similar results have been found with health service use and costs increasing with neighbourhood deprivation [13,65]. Inequality due to employment also suggests that those facing joblessness incur greater expense, supporting the second hypothesis. In China and Bangladesh there is a gradient where unemployed people incur higher direct costs than those employed. Retired patients have the highest direct healthcare costs in both studies, although this might be due to age and higher odds of costlier complications and comorbidities. Associations with unemployment might be due to the severity of the disease, which was not ascertained in either study, but which could explain higher direct costs. Leaving the labour market due to disease creates a higher risk for patients who are already in vulnerable sectors of the population such as people with low socioeconomic standing [66]. Patients with T2DM have an increased risk of stopping working prematurely and of experiencing unemployment which imposes costs on the economy as a whole [67]. Regarding employment, it is worth mentioning that some specific occupations have been associated with increased risk of T2DM and its complications such as night-shift workers [68], drivers and cleaners [69] but no studies of costs in these populations were found. The Indian study showing no significant difference in direct costs according to employment status [37] had a source population of predominantly middle- and high-income patients in Delhi; therefore, the unemployed population was not equivalent to those from China or Bangladesh. In Indonesia, direct medical costs were not associated with employment nor income, but lost productivity was related to income. This country is moving towards a universal healthcare system and T2DM treatment costs are covered [29]. Inequality driven by ethnicity was probably the domain with fewest conflicting results. US based studies that assessed ethnicity all agreed that the white people with T2DM had the highest direct and indirect costs. The effect of ethnicity on diabetic healthcare service use and costs in US ethnic minorities has been attributed to a mixture of economic factors and insurance status. However, some studies adjusted for these variables and still found significant differences which might point out to underlying systemic inequalities such as racism in the provision of care to ethnic minorities. There is evidence that ethnic minorities have increased odds of therapeutic inertia, including delays in initiating insulin when glycaemic targets are not met [70,71]. As insulin is a much more expensive treatment, underlying issues regarding ethnic differences in this variable need to be addressed as might explain decreased healthcare costs in these demographics. People from Hispanic and Black groups have increased odds of worse T2DM outcomes. The extent of the effect of less healthcare resource use and decreased costs in treatment outcomes needs to be further explored. Two other ethnic minorities were included in the review with different patterns. The Hui Chinese were compared to the majority Han in China. The Hui have shown to have increased prevalence of metabolic syndrome [72] and cardiovascular disease [73]. This might explain why only in the 90th quintile of costs, the costs are greater than in the Han even after adjusting for confounders. In all other quintiles, the crude cost is lower but is explained by lower education and income which also affects this minority group. Lower cost in lower quintiles might be explained by healthcare foregone owing to delayed healthcare seeking, especially if patients from minority groups must pay for it or have inflexible working hours. In Canada, the increased costs in the aboriginal minority are potentially explained by the severity of the disease. Besides genetic factors, this population has been generationally isolated and restricted in healthy food choices. Also, their hunting and fishing culture has been impeded which caused a shift in their lifestyle [74]. It is worth noting that, different to the US, in Canada healthcare is free at the point of delivery which might also explain the change of patterns. These hypotheses may reflect different stages of healthcare utilisation among people experiencing inequalities. The first hypothesis might be more applicable to earlier stages of the condition where preventive treatment is available but underused; while the second hypothesis might take predominance as the condition progresses. Given that studies were mainly cross-sectional, and costs were not ascertained longitudinally it is not feasible to explore this dynamic fully. This highlights the importance of evaluating cost trajectories as well as healthcare resource use alongside costs to get a better understanding where disparities emerge. Therefore, while both hypotheses seem to contradict each other, they might be part of a continuum of healthcare engagement by inequalities that warrants further research. Regarding indirect costs, it is expected that patients on lower incomes will have lower indirect costs because of worse paid jobs. This is supported by the lower indirect costs found in Bangladeshi rural population as their wages are significantly inferior [75]. Lower indirect costs were also found in unemployed, uninsured and less educated patients. These results are likely driven by fewer missed workdays and the lower cost of each missed workday. Uninsured workers and those with lower educational attainment are likely to be worse paid than those with insurance and will tend to lose fewer workdays because of the higher impact of lost wages. Higher education was associated with higher indirect costs. However, the only study that provided intangible costs, also provided years of life lost due to T2DM whose relationship with educational level is inverse. This highlights that measuring indirect costs, using the human capital approach where income is a main variable or intangible cost measured by the willingness to pay approach, might not provide a thorough picture of the impact of financial costs of T2DM in the life of a patient. Important policy implications arise from these findings. In countries with high rural OOP burden, expanding rural healthcare infrastructure alone may be insufficient; financial protection mechanisms such as subsidised transport to care or telemedicine reducing travel-related access barriers may be needed to convert foregone care into appropriate utilisation. In universal healthcare systems, the higher costs observed in less educated patients suggest health literacy interventions, particularly around T2DM self-management and primary care engagement, could reduce downstream complication costs. In OOP systems, the same intervention would need to be paired with financial protection, as health literacy alone cannot translate into care-seeking without addressing capacity to pay. As evidence shows a pattern of therapeutic inertia in insulin initiation among ethnic minorities, this becomes a target for quality improvement, monitoring time-to-insulin-initiation by ethnicity within healthcare systems could identify and address a concrete driver of the cost-outcome mismatch identified in this review. Our review has strengths and limitations. The wide search strategy allowed us to retrieve studies from all over the world which permitted a contextualised analysis of each SDH. We were able to answer to our research question which to the best of our knowledge has not been addressed in a systematic review before. However, we focused our search on peer-reviewed studies which might have left reports from grey literature or from non-indexed articles. No studies from Africa or South America were retrieved, regions with stark inequalities; this might be due to our choices of databases as African and South American studies are less likely to be indexed in the databases we chose [76,77]. The high heterogeneity of studies also warrants some discussion, especially in the components analysed which differ greatly between studies. This was due to the data available and the perspective that informed each analysis. Some studies included dental costs in their calculation of direct medical costs; some included cost of transportation as indirect costs while others considered this a direct non-medical cost. Although out-of-pocket expenditure is the dominant cost-bearing mechanism in several included countries, explicit OOP cost components were not reported. This underreporting is concerning given that OOP expenditure is the metric most directly linked to financial hardship and catastrophic health expenditure at the household level. Standardised guidelines on the reporting of cost studies might help overcome this limitation in the future and improve synthesis of the wealth of information provided. Future cost-of-illness studies in LMIC settings should disaggregate and report OOP expenditure as a distinct cost component. Not all studies reported statistical analysis by SDH nor adjusted estimates. The lack of adjustment for confounders such as age, comorbidities, or disease severity limits the ability to draw causal conclusions about the independent effect of each SDH on costs. We have indicated throughout Figs 2 and 3, and Table 3, whether each reported difference reflects crude or adjusted analysis, allowing readers to weight findings accordingly. Overall, this review retrieved more studies from countries with fragmented healthcare systems where healthcare is not universal and not free at the point of delivery. In countries where rural living is highly prevalent, living in rural areas is associated with decreased direct healthcare costs. In countries where healthcare coverage is not universal, being uninsured and from an ethnic minority is associated with decreased direct healthcare costs. As previously stated, this pattern might reflect healthcare foregone, determined by ability and willingness to pay rather than clinical need; however, this needs to be further evaluated. Studies should also assess how different SDHs behave together and impact costs. The gradients generated by unequal wealth and opportunity distribution are rarely unidimensional. People with less access to education are more likely to be unemployed or have low paid jobs which will lead to lower income. This vicious cycle of inequality needs to be further studied from a cost perspective to inform policies. We observe that individuals with higher incomes, better employment, and health insurance tend to incur in greater indirect costs compared to their less well-off counterparts. However, it would be necessary to know how this cost translates into total family income to have a better understanding of the true impact of the disease on the patient. Future research should prioritise three areas. First, studies from Africa and Latin America are needed to determine whether the foregone care and accumulated burden framework applies in contexts with different healthcare financing structures and SDH gradients. Second, longitudinal studies tracking costs alongside healthcare utilisation over time are needed to test whether foregone care in early disease stages predicts accumulated burden later, which cross-sectional studies cannot capture. Third, standardised cost reporting guidelines for SDH-stratified analyses would improve comparability across studies, particularly regarding the classification of direct, indirect, and intangible costs. This review makes several novel contributions. It is, to the best of our knowledge, the first systematic synthesis of T2DM costs by SDH. It demonstrates that the direction of cost inequality is not universal but is moderated by healthcare financing model. It proposes a conceptual framework for interpreting cost inequalities in chronic disease that warrants further empirical testing. Finally, it identifies critical geographic gaps in the literature, particularly the absence of evidence from Africa and Latin America, where SDH-driven inequalities are most pronounced. Inequality is a social and political construct. Societies have many options for organisation, and choosing one approach over others generates divisions of wealth [78]. This review highlights the differences in the economic consequences in the treatment of T2DM by residence, insurance status, and ethnicity. Addressing these disparities is crucial to ensure healthcare delivery is based on true clinical need rather than socio-economic factors. Supporting information PRISMA checklist. (DOC) Full search strategies for all databases. (DOCX) 9 Apr 2026 -->PONE-D-25-68922-->-->The cost of inequality in the treatment of Type 2 Diabetes: A systematic review-->-->PLOS One Dear Dr. Alarcón-Yaquetto, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Pasyodun Koralage Buddhika Mahesh Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following financial disclosure: [This study was funded by the Economic and Social Research Council, London Indisciplinary Social Science Doctoral Training Partnership (LISS-DTP ES/P000703/1) Project Reference 2606816]. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. Please remove any funding-related text from the manuscript. Funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Partly Reviewer #4: Partly Reviewer #5: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: N/A Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: N/A Reviewer #5: N/A ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No Reviewer #5: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Methodology (Systematic Review Standards) Although the article is presented as a systematic review, the details of the search strategy, inclusion/exclusion criteria, and study selection process are not sufficiently clear to allow for full replication of the study. Minimum information about the Quality and Risk of Bias Assessment No formal assessment of methodological quality or risk of bias of included studies was reported, which limits the validity and weight of the results. They only presented a table about the risk of bias without any explanation about the method. Descriptive Rather Than Analytical Synthesis The findings are largely descriptive, and no comparative or framework analysis is provided to explain how inequalities affect treatment costs. Limited Novelty and Added Value The novelty of the study compared to previous reviews is not clearly stated, and many of the results are replications of well-known findings in the existing literature. Policy and Practical Implications The policy and practical implications are stated in general terms and do not lead to specific, actionable Reviewer #2: Dear Editor First off, the authors did a great job setting the stage. The introduction clearly lays out why this is such an important question—type 2 diabetes is a massive global problem, and we know social factors play a huge role in who gets it and how they fare. But this review smartly focuses on a less-discussed angle: the actual financial cost of those inequalities. Their methods are top-notch too; they registered the study on PROSPERO, followed PRISMA guidelines for transparency, and searched a wide range of databases, which gives me a lot of confidence that they found the relevant research out there. The way they've presented all the data in the tables and figures is also really clear and helps you see the patterns at a glance. Now, where things get a bit tricky, and this is a common challenge in this type of research, is the sheer variety of how different studies define and measure things like 'education' or 'income.' This makes it hard to compare apples to apples, which is why they couldn't do a statistical meta-analysis and had to describe the results narratively. It's not the authors' fault at all; it's just the state of the literature, but it's a significant limitation that means we have to interpret the findings with a bit of caution. I also noticed they pulled a lot of data from the US and China, which is great, but it makes me wonder how these findings apply to places in Africa or South America, which are barely represented. The story of cost inequality might be very different there. And while they are clearly experts at analyzing the numbers, I felt the discussion could have gone a step further to really hammer home the 'so what?' for policymakers. For example, they highlight that in countries where people pay for care out-of-pocket, the poor and rural populations often spend less on treatment, likely because they simply can't afford it and may delay care. But in countries with universal healthcare, the pattern flips, and sometimes the less educated or those facing other disadvantages end up costing the system more, perhaps because of lower health literacy leading to more expensive emergency room visits down the line. That's a crucial insight, and the paper could have ended by more forcefully suggesting what this means for real-world policy—like the need for better health education programs or subsidized transportation for rural patients. But all in all, this is a high-quality review. It's rigorous, it's relevant, and it shines a light on a really important issue that doesn't get enough attention. My final judgment is that this is a valuable and well-executed study that adds a lot to our understanding of the economics of diabetes. It's a professional, expert piece of work, no doubt about it, and any researcher or policymaker in this field would benefit from reading it. 1. Title and Abstract • Could explicitly state the primary outcome (e.g., "cost differences by SDH") in the abstract. • "Cost of inequalities" is slightly ambiguous; "economic burden of health disparities" might be clearer. 2. Introduction • Overly broad definition of SDH (e.g., includes insurance, which is more of a healthcare access factor). • Could better distinguish biological sex from gender to justify exclusion. 3. Methods • SDH Operationalization: Inconsistent definitions (e.g., "ethnicity" vs. "race"). • Risk of Bias: No assessment for publication bias (e.g., funnel plots). • Data Synthesis: Percentage differences are useful but limit comparability due to heterogeneous SDH categorizations. 4. Results • Heterogeneity: High variability in cost components (e.g., "indirect costs" defined inconsistently) impedes synthesis. • Statistical Reporting: Some studies lack adjusted p-values (e.g., Figure 2), weakening causal inference. • OOP Costs: Underreported despite relevance in low/middle-income countries (LMICs). 5. Discussion • Policy Implications: Underdeveloped. Could suggest actionable strategies (e.g., insurance expansions, rural infrastructure). • Generalizability: Overreliance on US/China data (13/22 studies) limits global applicability. • Gender Exclusion: Justification is weak; gender influences health-seeking behavior and costs. 6. Conclusion • Lacks forward-looking recommendations (e.g., "future studies should..."). • Does not reiterate the public health significance of addressing cost inequalities. 7. Overall Assessment • Heterogeneity: Limits quantitative synthesis; meta-analysis was infeasible. • Geographic Bias: Underrepresentation of Africa/Latin America. • SDH Scope: Some factors (e.g., insurance) may not align with WHO SDH framework. 8. Recommendations for Improvement 1. Clarify SDH Definitions: Align with WHO SDH framework (e.g., exclude insurance). 2. Enhance Statistical Synthesis: Use random-effects models where possible; report confidence intervals. 3. Expand Policy Discussion: Propose interventions (e.g., subsidized care for low-income groups). 4. Address Gaps: Include gender, LMICs beyond Asia, and standardized cost components. 9. Final Judgment This is a high-quality systematic review with methodological rigor and significant contributions to understanding diabetes cost inequalities. minor Revision to address critiques would strengthen its impact. Reviewer #3: The authors conducted a rigorous systematic review including updates from H2 of 2025. As noted in the above section, the review has been performed appropriately and rigorously, and the underlying data/references are fully transparent. The topic is of interest, and the authors did a thorough job vetting of the literature. However, the discussion and how the authors deal with the question of cost of inequality in the treatment of Type 2 Diabetes can be better fleshed out. Part of the issue is the combining of a number of disparate countries into one review. I would recommend in the discussion potentially discussing the different determinants by region - i.e. US, Asia, Europe and Latin America and come up with conclusions by region as well as by factor (i.e. income, etc). Also, I know it may be a bit beyond the scope of this article, but there could be a paragraph in the discussion re policy recommendations to mitigate these disparities. Also, I think a bit more on why T2D was selected might be important for the reader - why this condition versus something else. In summary, the authors clearly did a very thorough job of conducting this research and I believe this topic is of high import. I just think that the discussion/story telling component needs to be refined so that the reader can better ascertain how the "cost of inequality" impacts his/her region as well as globally, where there may be different policy levers depending on geography to help mitigate these disparities. Reviewer #4: It was a systematic review with unclear question. A major revision is requested. 1- The title of the study should be updated as a clear question. I could not understand which of the following is related to your study. "Cost of inequality", "cost and inequality", "inequality in costs", or ... ? 2- In addition, you emphasized on SDH. The role of SDH should be clarified in the title. 3- The study objectives should be updated according to the above comments. 4- I suggest "thematic synthesis" to improve the quality of data synthesis and designing a thematic analysis graph. Reviewer #5: The aim of the study is to examine the cost of treating type 2 diabetes related to psychosocial determinants of health. Overall, I do not have major issues with the methodology, except for a few minor comments, such as adding dates in the abstract or clarifying the publication period. My major concern is with the results section. The title of the paper is confusing. After reading it, I expected to see a comparison showing the cost of type 2 diabetes based on social determinants of health. For example, I expected to see a table comparing costs across groups. However, the authors did not provide this. Instead, they categorized the findings into different social determinants of health, such as place of residence, employment, education, income, insurance, and ethnicity. This raises questions. First, this is an international study, and comparing education levels in some countries (e.g., low‑resource countries) to countries like the United States is mismatched. My second concern relates to the findings on ethnicity and race. Except for a few developed countries, such as England and the United States, where racial categories exist, the categorization for other countries does not make sense. It seems the authors may need to revise the aim to learn the association between SDOH and T2DM treatment or expenses not in viewpoint of patients but the healthcare system or maybe both. I have similar concerns with the discussion section. The authors selected several dimensions of social determinants of health and discussed findings, but the presentation is confusing. I am not sure how they intend to address these issues. If I were conducting this study, I would first compare the populations in each selected article and provide more information about the study populations—for example, gender distribution, age distribution, race distribution, income distribution, and education distribution, if available. Then I would add findings from each paper, such as out‑of‑pocket payments or cost of the treatment, which might be a useful metric for comparison, or other relevant elements the authors want to highlight. After that, I would compare treatment costs. I do not know how much the authors will benefit from my comments, but I hope they are helpful. Thank you for sharing. Minor comments: This is the review for PLOS One on the cost of inequality in the treatment of type 2 diabetes. The study performed a systematic review, but the timeframe is not clear. It seems the review was conducted in March 2025, going back to a study performed on February 6, 2023, with an update on October 5, 2025. However, the timeframe for the articles included in the study is not clearly stated. In some places, it is mentioned as 2000 to 2021. Please clarify the study period. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No Reviewer #3: No Reviewer #4: Yes: Seyyed Amir Yasin Ahmadi Reviewer #5: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: Dear Editor.docx 13 Jun 2026 Reviewer #1: Methodology (Systematic Review Standards) 1.1 Although the article is presented as a systematic review, the details of the search strategy, inclusion/exclusion criteria, and study selection process are not sufficiently clear to allow for full replication of the study. The review protocol was registered on PROSPERO, and the complete search strategy, including database specific search strings, is provided in Supplementary File 1. To improve reproducibility, we have expanded the Methods section to provide additional detail on the study selection and data extraction procedures. We have also clarified the dates of the original and updated searches and the databases searched. 1.2. Minimum information about the Quality and Risk of Bias Assessment No formal assessment of methodological quality or risk of bias of included studies was reported, which limits the validity and weight of the results. They only presented a table about the risk of bias without any explanation about the method. Thank you for your comment. We included a quality appraisal using the Larg and Moss checklist of cost-of-illness studies. We added information in the Methods section regarding the tool. 1.3 Descriptive Rather Than Analytical Synthesis The findings are largely descriptive, and no comparative or framework analysis is provided to explain how inequalities affect treatment costs. We have restructured the discussion to make explicit a conceptual framework comprising two hypotheses: foregone care and accumulated burden, that explain how inequalities affect T2DM treatment costs, moderated by healthcare system structure. While this framework was implicit in our original discussion, we have now named it explicitly, labelled each hypothesis clearly, and added a sentence at the end of each SDH subsection mapping findings onto the framework. We have also added a conceptual diagram illustrating the relationship between SDH, healthcare system type, and cost outcomes. Limited Novelty and Added Value The novelty of the study compared to previous reviews is not clearly stated, and many of the results are replications of well-known findings in the existing literature. We have strengthened the novelty statement in two places. In the introduction, we now state that this is, to the best of our knowledge, the first systematic review to synthesise economic costs of T2DM by SDH, and clarify that cost patterns represent a distinct and policy-relevant dimension of inequality that does not necessarily mirror clinical findings. We also distinguish our contribution from prior reviews on SDH and T2DM outcomes, which have focused on prevalence, complications, and glycaemic control rather than costs. While individual findings replicate well-known associations between SDH and health outcomes, the contribution of this review lies not in the direction of individual associations which may be anticipated but in the findings that the direction of cost inequality is moderated by healthcare system structure; the foregone care and accumulated burden hypotheses that explain this moderation; and the documentation of geographic gaps in cost research by SDH. We have made these contributions more explicit throughout the discussion. Policy and Practical Implications The policy and practical implications are stated in general terms and do not lead to specific, actionable Thank you for highlighting this. We have now included policy and practical implications in the discussion. Reviewer #2: Dear Editor First off, the authors did a great job setting the stage. The introduction clearly lays out why this is such an important question—type 2 diabetes is a massive global problem, and we know social factors play a huge role in who gets it and how they fare. But this review smartly focuses on a less-discussed angle: the actual financial cost of those inequalities. Their methods are top-notch too; they registered the study on PROSPERO, followed PRISMA guidelines for transparency, and searched a wide range of databases, which gives me a lot of confidence that they found the relevant research out there. The way they've presented all the data in the tables and figures is also really clear and helps you see the patterns at a glance. Thank you for your kind comments. Now, where things get a bit tricky, and this is a common challenge in this type of research, is the sheer variety of how different studies define and measure things like 'education' or 'income.' This makes it hard to compare apples to apples, which is why they couldn't do a statistical meta-analysis and had to describe the results narratively. It's not the authors' fault at all; it's just the state of the literature, but it's a significant limitation that means we have to interpret the findings with a bit of caution. I also noticed they pulled a lot of data from the US and China, which is great, but it makes me wonder how these findings apply to places in Africa or South America, which are barely represented. The story of cost inequality might be very different there. And while they are clearly experts at analyzing the numbers, I felt the discussion could have gone a step further to really hammer home the 'so what?' for policymakers. For example, they highlight that in countries where people pay for care out-of-pocket, the poor and rural populations often spend less on treatment, likely because they simply can't afford it and may delay care. But in countries with universal healthcare, the pattern flips, and sometimes the less educated or those facing other disadvantages end up costing the system more, perhaps because of lower health literacy leading to more expensive emergency room visits down the line. That's a crucial insight, and the paper could have ended by more forcefully suggesting what this means for real-world policy—like the need for better health education programs or subsidized transportation for rural patients. Thank you for pointing this out. As suggested, we have enhanced the discussion section. First by interpreting the results in light of two proposed hypothesis and by expanding the policy implications of the findings including the need for better health education and subsidized transportation. But all in all, this is a high-quality review. It's rigorous, it's relevant, and it shines a light on a really important issue that doesn't get enough attention. My final judgment is that this is a valuable and well-executed study that adds a lot to our understanding of the economics of diabetes. It's a professional, expert piece of work, no doubt about it, and any researcher or policymaker in this field would benefit from reading it. Thank you for your comments. 1. Title and Abstract • Could explicitly state the primary outcome (e.g., "cost differences by SDH") in the abstract. We have modified the abstract to state the primary outcome as suggested. • "Cost of inequalities" is slightly ambiguous; "economic burden of health disparities" might be clearer. We have modified the title as suggested. 2. Introduction • Overly broad definition of SDH (e.g., includes insurance, which is more of a healthcare access factor). As suggested, we removed insurance as one of the analysed SDH and now align with the WHO SDH framework. • Could better distinguish biological sex from gender to justify exclusion. On page 5, we have expanded the explanation of gender vs sex differences. 3. Methods • SDH Operationalization: Inconsistent definitions (e.g., "ethnicity" vs. "race"). Thank you for your comment. We have acknowledged the differences between race and ethnicities in the methods section. Unfortunately, most of the included studies use both terms interchangeably, where studies explicitly used racial rather than ethnic categories, we retain the original authors’ terminology. • Risk of Bias: No assessment for publication bias (e.g., funnel plots). Thank you for the suggestion. Unfortunately, given the high heterogeneity of the studies retrieved, a meta-analysis was not feasible. Therefore, no effect sizes for each independent study could be calculated and no publication bias assessment is feasible. • Data Synthesis: Percentage differences are useful but limit comparability due to heterogeneous SDH categorizations. We acknowledge this limitation. We added a paragraph making this clear in the methods section, as well as in the discussion section. 4. Results • Heterogeneity: High variability in cost components (e.g., "indirect costs" defined inconsistently) impedes synthesis. Statistical Reporting: Some studies lack adjusted p-values (e.g., Figure 2), weakening causal inference. OOP Costs: Underreported despite relevance in low/middle-income countries (LMICs). We acknowledge all the points raised by the reviewer as limitations. We have included paragraphs in the discussion explicitly acknowledging this. Documenting the extent of methodological inconsistency in T2DM cost-of-illness research stratified by SDH is in itself a finding and suggestions to improve future studies are now provided in the discussion section. 5. Discussion • Policy Implications: Underdeveloped. Could suggest actionable strategies (e.g., insurance expansions, rural infrastructure). Thank you for highlighting the need for enhanced policy implications. We have now added actionable for strategies according to our findings in the discussion section. • Generalizability: Overreliance on US/China data (13/22 studies) limits global applicability. Thank you for your comment. Our interpretation was more focused on healthcare models rather than geography. The US and China represent contrasting models within our framework, the US being a mixed, insurance-based system while China represents a system in active transition toward universal coverage but with persistent OOP burden, particularly in rural areas. The contrast between these two contexts allowed us to observe that the direction of cost inequality by SDH appears to be moderated by healthcare financing structure rather than being a fixed, universal pattern. We suggest that the generalizability of our findings should be considered less in terms of geographic representativeness and more in terms of the range of healthcare financing models represented. Nonetheless, we agree this is an important limitation and have strengthened our limitations section to explicitly recommend that future studies from underrepresented regions are needed to test whether the conceptual framework proposed in this review holds in those contexts. • Gender Exclusion: Justification is weak; gender influences health-seeking behavior and costs. This is correct. However, in the studies included, gender is not operationalised as a the socially constructed characteristics rather than sex. We have included a more ample explanation of this in the methods section as well as in the discussions section calling for a proper categorisation of gender. 6. Conclusion • Lacks forward-looking recommendations (e.g., "future studies should..."). We have now included a paragraph about future studies, establishing the main gaps the review found. • Does not reiterate the public health significance of addressing cost inequalities. In the discussion section, we have added a closing statement to the conclusion explicitly reiterating the public health significance of addressing cost inequalities in T2DM treatment. 7. Overall Assessment • Heterogeneity: Limits quantitative synthesis; meta-analysis was infeasible. This is correct. We state in the paper that meta-analysis was not feasible. • Geographic Bias: Underrepresentation of Africa/Latin America. This limitation is very concerning given the inequalities observed in these regions. We clearly state the need for research in these regions • SDH Scope: Some factors (e.g., insurance) may not align with WHO SDH framework. We have aligned our definition with the WHO SDH framework and as suggested removed insurance as one of the SDHs analysed. 8. Recommendations for Improvement 1. Clarify SDH Definitions: Align with WHO SDH framework (e.g., exclude insurance). We have aligned our definition with the WHO SDH framework and as suggested removed insurance as one of the SDHs analysed. 2. Enhance Statistical Synthesis: Use random-effects models where possible; report confidence intervals. Thank you for the suggestion. Random-effects meta-analysis requires pooled effect estimates with extractable standard errors across comparable outcomes. Given the substantial heterogeneity in SDH definitions, cost components, currencies, healthcare systems, and study designs across included studies, a pooled estimate would not be suitable. Regarding confidence intervals, the majority of included studies report group means alongside standard deviations or standard errors, but do not report variance measures for the difference between groups. Additionally, we were concerned that presenting confidence intervals alongside percentage differences could imply a level of cross-study comparability that our narrative and thematic synthesis approach does not claim nor support. We have retained percentage differences as a descriptive measure of the direction and approximate magnitude of cost gradients within each study, accompanied by significance levels as originally reported (crude and/or adjusted, as available). We believe this approach, combined with the thematic synthesis and conceptual framework added in response to other reviewer comments, provides a transparent and methodologically suitable synthesis given the nature of the available evidence. 3. Expand Policy Discussion: Propose interventions (e.g., subsidized care for low-income groups). We have added policy recommendations in the discussion section. Thank you for your suggestion. 4. Address Gaps: Include gender, LMICs beyond Asia, and standardized cost components. Regarding gender, we refer to our methods section, where we explain that gender was excluded as an SDH because it is rarely operationalised as such in the cost literature — studies predominantly report biological sex rather than gender identity or roles — and because biological sex, while relevant to T2DM prevalence, represents a biomedical rather than social determinant and falls outside the SDH framework as defined for this review. Regarding LMICs, we have expanded our discussion of healthcare financing models to address this, noting that countries such as Bangladesh, India, and Pakistan represent out-of-pocket-dominant systems, and have discussed the underreporting of OOP costs specifically in these contexts as both a finding and a limitation of the available evidence base. We have also added a recommendation in our conclusion for future studies from underrepresented LMIC regions, particularly Africa and Latin America. Regarding standardised cost components, we have addressed this in our discussion of heterogeneity, noting the inconsistent classification of cost components across studies (e.g. transportation costs classified as direct non-medical in some studies and indirect in others) and recommending that future cost-of-illness studies adopt standardised costing methods to improve comparability. 9. Final Judgment This is a high-quality systematic review with methodological rigor and significant contributions to understanding diabetes cost inequalities. minor Revision to address critiques would strengthen its impact. Thank you for your comments and very insightful suggestions. Reviewer #3: The authors conducted a rigorous systematic review including updates from H2 of 2025. As noted in the above section, the review has been performed appropriately and rigorously, and the underlying data/references are fully transparent. The topic is of interest, and the authors did a thorough job vetting of the literature. Thank you for your comments. However, the discussion and how the authors deal with the question of cost of inequality in the treatment of Type 2 Diabetes can be better fleshed out. Part of the issue is the combining of a number of disparate countries into one review. I would recommend in the discussion potentially discussing the different determinants by region - i.e. US, Asia, Europe and Latin America and come up with conclusions by region as well as by factor (i.e. income, etc). Than 6 Jul 2026 The economic burden of Type 2 Diabetes by social determinants of health: A systematic review PONE-D-25-68922R1 Dear Dr. Alarcón-Yaquetto, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Pasyodun Koralage Buddhika Mahesh Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #3: All comments have been addressed Reviewer #4: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #3: Yes Reviewer #4: (No Response) ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #3: Yes Reviewer #4: (No Response) ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #3: Yes Reviewer #4: (No Response) ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #3: Yes Reviewer #4: (No Response) ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #3: Thank you for revising the manuscript to incorporate my comments. I believe the manuscript reads better and will help contribute to the literature. Reviewer #4: The corrections were satisfying. The manuscript is acceptable for publication. Best wishes for the authors. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #3: Yes: Jamie Partridge Grossman Reviewer #4: Yes: Seyyed Amir Yasin Ahmadi ********** PONE-D-25-68922R1 PLOS One Dear Dr. Alarcón-Yaquetto, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Pasyodun Koralage Buddhika Mahesh Academic Editor PLOS One